Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ORIC
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Bong Y. Koh | 4.32M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Nimish Shah | 4.32M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | VHCP Management EG, LLC | 4.32M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | VHCP Management III, LLC | 4.32M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 4.32M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | VHCP Co-Investment Holdings III, LLC | 4.32M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 4.32M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Steven A. Cohen | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Point72 Capital Advisors, Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Point72 Asset Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Rose Sharon Shabet | 8.26M | 7.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Halvorsen Ole Andreas | 8.26M | 7.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Viking Global Opportunities Drawdown (Aggregator) LP | 3.01M | 2.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Viking Global Opportunities Drawdown Portfolio GP LLC | 3.01M | 2.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Viking Global Opportunities Drawdown GP LLC | 3.01M | 2.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.25M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Viking Global Opportunities Portfolio GP LLC | 5.25M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Viking Global Opportunities GP LLC | 5.25M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Viking Global Opportunities Parent GP LLC | 8.26M | 7.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Viking Global Investors LP | 8.26M | 7.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | ORIC Oric Pharmaceuticals, Inc. | T. Rowe Price Associates, Inc. | 5.39M | 5.4% | SCHEDULE 13G ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Pfizer Inc. (IRS Identification No.: 13-5315170) | 3.44M | 3.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Bong Y. Koh | 5.68M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Nimish Shah | 5.68M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | VHCP Management EG, LLC | 5.68M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | VHCP Management III, LLC | 5.68M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 5.68M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | VHCP Co-Investment Holdings III, LLC | 5.68M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 5.68M | 5.8% | SCHEDULE 13G/A ↗ |
| Jan 21, 2026 | SCHEDULE 13G | ORIC Oric Pharmaceuticals, Inc. | BlackRock, Inc. | 5.47M | 5.6% | SCHEDULE 13G ↗ |
| Nov 17, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Peter Svennilson | 3.64M | 3.7% | SCHEDULE 13G/A ↗ |
| Nov 17, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | David V Goeddel | 3.63M | 3.7% | SCHEDULE 13G/A ↗ |
| Nov 17, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | The Column Group II GP, LP | 3.54M | 3.6% | SCHEDULE 13G/A ↗ |
| Nov 17, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | The Column Group II, LP | 3.54M | 3.6% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Panayotis D. Sparaggis | 4.50M | 4.6% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Alkeon Capital Management LLC | 4.50M | 4.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Rocco Sgobbo | 7.16M | 8.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Costas Constantinides | 7.16M | 8.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Ian Charoub | 7.16M | 8.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Nextech Crossover I SCSp | 7.16M | 8.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Nextech Crossover I GP S.a. r.l. | 7.16M | 8.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13D/A (amended) | ORIC Oric Pharmaceuticals, Inc. | George Simeon | 4.62M | 4.8% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13D/A (amended) | ORIC Oric Pharmaceuticals, Inc. | SR One Capital Partners II, LP | 694,859 | 0.7% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13D/A (amended) | ORIC Oric Pharmaceuticals, Inc. | SR One Capital Fund II Aggregator, LP | 694,859 | 0.7% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13D/A (amended) | ORIC Oric Pharmaceuticals, Inc. | SR One Capital SMA Partners, LP | 1.54M | 1.6% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13D/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Amzl, LP | 1.54M | 1.6% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13D/A (amended) | ORIC Oric Pharmaceuticals, Inc. | SR One Capital Opportunities Partners I, LP | 2.38M | 2.5% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13D/A (amended) | ORIC Oric Pharmaceuticals, Inc. | SR One Capital Opportunities Fund I, LP | 2.38M | 2.5% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13D/A (amended) | ORIC Oric Pharmaceuticals, Inc. | SR One Capital Management, LLC | 4.62M | 4.8% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ORIC Oric Pharmaceuticals, Inc. | Rose Sharon Shabet | 8.73M | 10.0% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:19 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances